Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TY101 Phase 1/2 Trial in Advanced Solid Tumors and Lymphomas
NCT04458389Phase 2Unknown
- Sponsor
- Tayu Huaxia Biotech
- Start
- Dec 2020
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of TY101 in solid tumor, lymphoma, peripheral T-cell lymphoma (PTCL), squamous cell carcinoma of the skin (SCC), sponsored by Tayu Huaxia Biotech. Status: unknown.
02
Drugs
TY101
03
Conditions
solid tumorlymphomaperipheral T-cell lymphoma (PTCL)squamous cell carcinoma of the skin (SCC)
Beyond the preview
Go deeper on NCT04458389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04458389.